Managing type 2 diabetes: Going beyond glycemic control

Journal of Managed Care Pharmacy

Volumn 14, Issue 5 SUPPL. B, 2008, Pages

  Stolar, Mark W ^a   Hoogwerf, Byron J ^b   Gorshow, Stephen M ^c   Boyle, Patrick J ^d   Wales, Dirk O ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Great West Healthcare   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Texas HealthSpring/GulfQuest   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMINOTRANSFERASE; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GENERIC DRUG; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; UNINDEXED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ARTERIAL WALL THICKNESS; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CYANOCOBALAMIN DEFICIENCY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FLATULENCE; FLUID RETENTION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIP FRACTURE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PANCREATITIS; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SUBCUTANEOUS FAT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WRIST FRACTURE;

ALGORITHMS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; INSULIN; LIPIDS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 48449104660     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278-83.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: United States, 2005. Available at: http://apps.nccd.cdc.gov/ ddtstrs/template/ndfs_2005.pdf. Accessed September 11, 2007.
3. Centers for Disease Control and Prevention. National Diabetes Surveillance System. Diabetes data and trends. Available at: www.cdc.gov/ diabetes/statistics/index.htm. Accessed September 26, 2007.
4. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29:2114-16.
5. Centers for Disease Control and Prevention. Division of Nutrition, Physical Activity and Obesity. Overweight and obesity. Available at: www.cdc.gov/nccdphp/dnpa/obesity/index.htm. Accessed September 12, 2007.
6. Witt L. Why we're losing the war against obesity. Am Demogr. 2003; 25:27-31.
7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-32.
8. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care. 2002;25:476-81.
9. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300-04.
10. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes. Diabetes Care. 2007;30:1281-92.
11. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care. 2002;25:23-29.
12. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006;12:130-42. Available at: www.amcp.org/data/jmcp/suby_review_130-142.pdf.
13. National Committee for Quality Assurance. The state of health care quality 2007. Available at: http://web.ncqa.org/tabid/543/Default.aspx. Accessed September 26, 2007.
14. Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Lafata JE. The impact of diabetes on employment and work productivity. Diabetes Care. 2005;28:2662-67.
15. Van der Does FEE, De Neeling JND, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996;19:204-10
16. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. JAMA. 1998;280:1490-06.
17. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
18. Stratton IM, Adler Al, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
19. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11:559-64. Available at: www.amcp.org/data/jmcp/Original%20Research_559_564.pdf.
20. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59-64.
21. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001;24:51-55.
22. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-89.
23. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4:23-31.
24. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
25. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
26. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13(suppl 1):1-68.
27. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol. 2007;99:51B-67B.
28. National Heart, Lung, and Blood Institute. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease. Press release; February 6, 2008. Available at: www.nih.gov/news/health/feb2008/nhlbi-06.htm. Accessed March, 18, 2008.
29. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99:21i-33i.
30. National Heart, Lung, and Blood Institute. ACCORD telebriefing prepared remarks. Wednesday, February 6, 2008. Available at: www.nhlbi.nih.gov/ health/prof/heart/other/accord/remarks.pdf. Accessed April 28, 2008.
31. National Heart, Lung, and Blood Institute. Questions and answers: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. February 6, 2008. Available at: www.nhlbi.nih.gov/health/prof/heart/other/accord/ q_a.htm. Accessed April 28, 2008
32. DeFronzo RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667-87.
33. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diabetes. 2000;18:80-84.
34. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-78.
35. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717-23.
36. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753-59.
37. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47:31-39.
38. Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther. 2003;25(suppl B):B32-B46.
39. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-803.
40. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517-22.
41. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454-70.
42. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30:1344-50.
43. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435-49.
44. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72.
45. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
46. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride tablets); Glucophage XR (metformin hydrochloride extended-release tablets) [prescribing information]. June, 2006.
47. Ting RZ, Szeto CC, Chan MH, Ma KR, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med. 2006; 166:1975-79.
48. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.
49. United Kingdom Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-58.
50. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21-31.
51. Polonsky WH, Fisher C, Guzman S, Villa-Caballero L, Fdelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-55.
52. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone. 2006;8(suppl 2):S19-S26.
53. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR α/ γ agonists: promises and pitfalls in type 2 diabetes. Am J Ther. 2007;14:49-62.
54. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-43.
55. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003; 111:405-14.
56. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes. 2005;54:880-85.
57. Takeda Pharmaceuticals America Inc. Actos (pioglitazone hydrochloride) Tablets [prescribing information]. August, 2007.
58. GlaxoSmithKline. Avandia (rosiglitazone maleate) Tablets [prescribing information]. November, 2007.
59. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; 91:3349-54.
60. Meier C, Kraenzlin ME, Bodmer M,Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820-25.
61. Gilling L, Suwattee P, DeSouza C, Asnani S, Fonseca V. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs. 2002;2:149-56.
62. Kelly AS, Bank AJ. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications. 2007;21:326-34.
63. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-54.
64. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-81.
65. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
66. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007; 49:1772-80.
67. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865-73.
68. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773-78.
69. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-88.
70. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-71.
71. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356:2522-24.
72. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-95.
73. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 2007;16:1065-71.
74. Lago RM, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-36.
75. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med. 2007;357:844-46.
76. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007; 357:28-38.
77. Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care. 2006;29:154-57.
78. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395-409.
79. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
80. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48:1093-104.
81. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230-35.
82. Amylin Pharmaceuticals Inc. Byetta (exenatide) injection [prescribing information]. 2007.
83. Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000;108:15S-22S.
84. UKPDS Study Group. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998;21:87-92.
85. Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in type 2 diabetes in the UK. Diabet Med. 2007;24:982-1002.
86. Garber AJ. Vascular disease and lipids in diabetes. Med Clin North Am. 1998;82:931-48.
87. Lyseng-Williamson KA. Sitagliptin. Drugs. 2007;67:587-97.
88. U.S. Food and Drug Administration. Information for healthcare professionals: exenatide (marketed as Byetta). Available at: www.fda.gov/ cder/drug/InfoSheets/HCP/exenatideHCP.htm. Accessed November 8, 2007.